Published April 8, 2026 | Version v1

Targeting Apoptotic Dysregulation in Cancer: From Molecular Mechanisms to Clinical Therapeutics

Authors/Creators

Description

Apoptosis, or programmed cell death, is a highly regulated biological process essential for tissue homeostasis. Its dysregulation is a fundamental hallmark of cancer, enabling malignant cells to survive genotoxic stress, accumulate mutations, and resist conventional therapies. This detailed technical review examines the molecular mechanisms underlying apoptotic evasion in cancer and the therapeutic strategies designed to reactivate these death pathways. The intrinsic apoptotic pathway is primarily governed by the BCL-2 protein family, which regulates mitochondrial outer membrane permeabilization (MOMP). Cancer cells frequently overexpress anti-apoptotic members like BCL-2, BCL-xL, and MCL-1 to prevent MOMP. Conversely, the extrinsic pathway is initiated by death receptors (e.g., Fas, TRAIL receptors) and is often suppressed in tumors via receptor downregulation or overexpression of inhibitory proteins like c-FLIP. Additionally, mutations in the p53 tumor suppressor and overexpression of Inhibitor of Apoptosis Proteins (IAPs) further dismantle the cellular death machinery. To counter these evasion tactics, researchers have developed targeted apoptosis modulators. BH3 mimetics, notably the FDA-approved BCL-2 inhibitor venetoclax, have transformed the treatment of hematological malignancies by directly displacing pro-apoptotic proteins to trigger MOMP. Other promising therapeutic avenues include p53 reactivators (e.g., Rezatapopt), SMAC mimetics that antagonize IAPs, and next-generation TRAIL receptor agonists. However, clinical efficacy is frequently limited by adaptive resistance mechanisms, such as the compensatory upregulation of alternative anti-apoptotic proteins or metabolic reprogramming. The review emphasizes the necessity of robust experimental frameworks, detailing core assays like Annexin V/PI flow cytometry, caspase activity measurements, and dynamic BH3 profiling to assess mitochondrial priming. Emerging biomarker platforms, such as conformation-specific PRIMABs, offer improved patient stratification. Ultimately, the article advocates for rationally designed combination regimens pairing apoptotic modulators with conventional chemotherapy, targeted agents, or immunotherapy to simultaneously block multiple survival nodes, overcome tumor plasticity, and achieve durable clinical responses. Source: https://www.apoptosisstudy.com/posts/targeting-apoptotic-dysregulation-in-cancer-from-molecular-mechanisms-to-clinical-therapeutics

Files

report.pdf

Files (2.3 MB)

Name Size
md5:b5711966687ef76b47826d6765cd731e
2.3 MB Preview Download